Cargando…

Virtual Therapy with the NMDA Antagonist Memantine in Hippocampal Models of Moderate to Severe Alzheimer’s Disease, In Silico Trials

The variability in clinical trial results on memantine treatment of Alzheimer’s disease remains incompletely explained. The aim of this in silico study is a virtual memantine therapy for Alzheimer’s disease that provides a different perspective on clinical trials; An in silico randomised trial using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Świetlik, Dariusz, Białowąs, Jacek, Kusiak, Aida, Krasny, Marta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145937/ https://www.ncbi.nlm.nih.gov/pubmed/35631372 http://dx.doi.org/10.3390/ph15050546

Ejemplares similares

The Computer Simulation of Therapy with the NMDA Antagonist in Excitotoxic Neurodegeneration in an Alzheimer’s Disease-like Pathology
por: Świetlik, Dariusz, et al.
Publicado: (2022)

Computational Modeling of Therapy with the NMDA Antagonist in Neurodegenerative Disease: Information Theory in the Mechanism of Action of Memantine
por: Świetlik, Dariusz, et al.
Publicado: (2022)

Computer Model of Synapse Loss During an Alzheimer’s Disease-Like Pathology in Hippocampal Subregions DG, CA3 and CA1—The Way to Chaos and Information Transfer
por: Świetlik, Dariusz, et al.
Publicado: (2019)

Computer Modeling of Alzheimer’s Disease—Simulations of Synaptic Plasticity and Memory in the CA3-CA1 Hippocampal Formation Microcircuit
por: Świetlik, Dariusz, et al.
Publicado: (2019)

Effects of Inducing Gamma Oscillations in Hippocampal Subregions DG, CA3, and CA1 on the Potential Alleviation of Alzheimer’s Disease-Related Pathology: Computer Modeling and Simulations
por: Świetlik, Dariusz, et al.
Publicado: (2019)

Application of Artificial Neural Networks to Identify Alzheimer’s Disease Using Cerebral Perfusion SPECT Data
por: Świetlik, Dariusz, et al.
Publicado: (2019)

Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
por: Kikuchi, Tetsuro
Publicado: (2020)

Effects of Memantine, an NMDA Antagonist, on Metabolic Syndromes in Female NMRI Mice
por: Osanloo, Naser, et al.
Publicado: (2015)

The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi
por: Santos Souza, Higo Fernando, et al.
Publicado: (2019)

Artificial Intelligence in Dentistry—Narrative Review
por: Ossowska, Agata, et al.
Publicado: (2022)

Evaluation of the Progression of Periodontitis with the Use of Neural Networks
por: Ossowska, Agata, et al.
Publicado: (2022)

Progression of Selected Parameters of the Clinical Profile of Patients with Periodontitis Using Kohonen’s Self-Organizing Maps
por: Ossowska, Agata, et al.
Publicado: (2023)

Memantine has a nicotinic neuroprotective pathway in acute hippocampal slices after an NMDA insult
por: Ferrer-Acosta, Yancy, et al.
Publicado: (2022)

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer’s disease in the Netherlands
por: Hoogveldt, Bart, et al.
Publicado: (2011)

A pilot investigation into the influence of electronic cigarettes on oral bacteria
por: Cichońska, Dominika, et al.
Publicado: (2022)

Memantine, an Antagonist of the NMDA Glutamate Receptor, Affects Cell Proliferation, Differentiation and the Intracellular Cycle and Induces Apoptosis in Trypanosoma cruzi
por: Damasceno, Flávia Silva, et al.
Publicado: (2014)

Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
por: Puangthong, Umamon, et al.
Publicado: (2009)

Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)
por: Knapp, Martin, et al.
Publicado: (2016)

Influence of Electronic Cigarettes on Selected Antibacterial Properties of Saliva
por: Cichońska, Dominika, et al.
Publicado: (2019)

Caries intensity and Streptococcus mutans in the saliva of patients with Turner syndrome
por: Kusiak, Aida, et al.
Publicado: (2021)

Influence of Electronic Cigarettes on Selected Physicochemical Properties of Saliva
por: Cichońska, Dominika, et al.
Publicado: (2022)

Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantine
por: Pringle, A, et al.
Publicado: (2012)

Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity
por: Lopes, João P, et al.
Publicado: (2013)

The effect of the NMDA channel blocker memantine on salicylate-induced tinnitus in rats
por: RALLI, M., et al.
Publicado: (2014)

Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease
por: Takahashi, Hiroto, et al.
Publicado: (2015)

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
por: Jones, Rob, et al.
Publicado: (2009)

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials
por: Molino, Ivana, et al.
Publicado: (2013)

Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease
por: Rive, Benoît, et al.
Publicado: (2013)

High oral carriage of multidrug resistant Gram-negative bacilli in adolescents: the SOPKARD-Junior study
por: Katkowska, Marta, et al.
Publicado: (2023)

The NMDA antagonist memantine affects training induced motor cortex plasticity – a study using transcranial magnetic stimulation [ISRCTN65784760]
por: Schwenkreis, Peter, et al.
Publicado: (2005)

The Analysis of the Frequency of Leukoplakia in Reference of Tobacco Smoking among Northern Polish Population
por: Kusiak, Aida, et al.
Publicado: (2020)

Corrigendum: Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease
por: Takahashi, Hiroto, et al.
Publicado: (2016)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
por: Deardorff, William James, et al.
Publicado: (2016)

Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer’s disease
por: Chang, Wenguang, et al.
Publicado: (2018)

Application of Real-World Data and the REWARD Framework to Detect Unknown Benefits of Memantine and Identify Potential Disease Targets for New NMDA Receptor Antagonists
por: Kern, David M., et al.
Publicado: (2021)

Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine
por: Schmidt, R, et al.
Publicado: (2008)

Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
por: Tampi, Rajesh R, et al.
Publicado: (2007)

Update on the use of memantine in Alzheimer’s disease
por: van Marum, Robert J
Publicado: (2009)

Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer's disease: A clinical trial
por: Zhou, Tiantian, et al.
Publicado: (2019)

Memantine Improves Cognitive Function and Alters Hippocampal and Cortical Proteome in Triple Transgenic Mouse Model of Alzheimer's Disease
por: Zhou, Xinhua, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tr75ip9v326dobfq6slndsjvne